1130 results about "Globulin" patented technology

The invention provides an egg yolk globulin powder processing traceability method and system, and the method comprises the steps: carrying out the multi-node monitoring of each processing traceability process through a block chain technology, and carrying out the chain packaging of a processing dependency relationship between adjacent processing traceability processes and a time certificate provided by an authority timestamp service; generating a chained association block between adjacent processing nodes in each processing traceability process; performing digital signature on the initial identification code of the egg yolk globulin powder raw material, the processing node information of each processing traceability process and the combined data of the preorder data block hash value, and generating a credible voucher of each processing traceability process; jointly constructing a traceability node of each processing traceability process based on the credible voucher of each processing traceability process, the processing node information and the chained association block; and generating a tamper-resistant full-process tracing chain of the egg yolk globulin powder based on each tracing node. Based on the scheme, cross-link credible association in egg yolk globulin powder processing traceability can be realized.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention relates to the technical field of microorganisms, and discloses a lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 and an application thereof in improving an immune function, the lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 is preserved in the China General Microbiological Culture Collection Center (CGMCC), the preservation number is CGMCC NO.30047, and the preservation time is March 18, 2024. The lactobacillus delbrueckii subsp. Bulgaricus XJFY201503 can be used for directly improving the immune function of an immunosuppressive mouse by protecting and maintaining normal physiological structures of central and peripheral immune organs and promoting secretion of serum cytokines and immune globulins; and the immune function of the mouse can be indirectly promoted by relieving intestinal inflammation reaction.

Chimeric antigen receptors that include an antigen recognition domain; a spacer domain derived from a modified immunoglobulin Fc region having one or more mutations in its CH2 region resulting in impaired binding to an FcR; and an intracellular signaling domain.

The invention relates generally to compositions and methods for purifying the desired species from a mixture of desired heterodimer and contaminating homodimer immunoglobulin variants by modifying the isoelectric point(s) of the individual chains.

The invention discloses a composite microecological preparation as well as a preparation method and application thereof. The compound microecological preparation disclosed by the invention comprises lactobacillus casei, lactobacillus plantarum and saccharomyces cerevisiae. The application effect of the composite microecological preparation in cow breeding is remarkable, the optimal addition amount of the composite microecological preparation is 100 mL / cow / day, the production performance of lactating cows can be improved, the milk yield is improved by 3.30 kg / cow / day, the milk yield of 4% standard milk is improved by 3.78 kg / cow / day, the total protein is improved by 15.9%, the albumin is improved by 14.7%, the globulin is improved by 16.5%, and the somatic cell number is reduced by 52.6%; and pollutant emission can be reduced, including 37.2% of ammonia emission reduction and 28.7% of carbon dioxide emission reduction.

The present invention relates to a binding agent capable of specifically binding and competitively inhibiting neutrophil elastase, the binding agent comprising an immunoglobulin single variable domain (ISVD), as well as related products, methods and uses, for example, methods and uses, particularly for the prevention, treatment or diagnosis of inflammatory diseases.

The invention discloses a preparation method of immunoglobulin composite liposome nanoparticles with a controlled release characteristic, and belongs to the field of food nutrition and functional factors. Cholesterol and sitosterol are creatively used as auxiliary supports of a lecithin liposome skeleton, the stability of an immunoglobulin liposome nanoparticle structure is improved, the slow release property in the simulation effect process is improved, and a pH response type hydrogel film formed based on electrostatic crosslinking is prepared from calcium alginate and chitosan. A more stable double-layer shell-core structure is formed, so that the stability of embedded immune globulin molecules in gastric juice is further improved, and fixed-point slow release in small intestines is realized.

This invention belongs to the field of nutritional composition technology, specifically disclosing a composition for promoting brain cognitive development, its preparation method, and its application. The composition for promoting brain cognitive development provided by this invention includes transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA, and further specifies that the mass ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA is (0.1~1.4) ng:(40000~160000) mg:(20000~60000) mg:(20000~70000) mg. In this invention, the preferred ratio of transforming growth factor, casein phosphopeptide, immunoglobulin, and sn-2 DHA can achieve the effect of promoting brain cognitive development through a multi-dimensional synergistic mechanism.

The invention provides a synthesis method of adsorption resin for removing immune globulin, and relates to a high polymer material synthesis technology, polyethylene glycol (PEG) or sulfobetaine (SBMA) is grafted through RAFT polymerization, the thickness of a grafting layer is 50-150nm, the nonspecific adsorption capacity of albumin is less than 5ng / cm < 2 >, photosensitive groups (such as phenyl azide) and ultraviolet light (254nm) are introduced to trigger crosslinking, and the coating shedding rate is less than 0.5% / time. According to the present invention, the cyclic stability is improved by 2 times, the Protein A directional capture antibody is grafted on the surface of the acrylic resin grafted with the polyethylene glycol or sulfobetaine, the IgG adsorption capacity achieves 150 mg / g, the specificity is more than 95%, the polyethylene glycol (PEG) is grafted on the surface of the magnetic particle by using ATRP / RAFT controllable polymerization, the organic solvent use amount is reduced by more than 80%, and the product adsorption capacity achieves 150 mg / g.

Described herein are methods for treating antibody mediated rejection of transplanted organs using inhibitors of IL-6. In one embodiment, the IL-6 inhibitor is Tocilizumab and is administered simultaneously or sequentially with intravenous immunoglobulin (IVIG).

The present invention pertains to protein oligomers for active immunization. Specifically, the invention relates to protein oligomers comprising at least a first monomer and a second 5 monomer, said at least first and second monomer comprising, in N- to C-terminal order, at least one first RBD, an immunoglobulin Fc (Ig Fc), and at least one second RBD, wherein a) Ig Fc has enhanced affinity for the neonatal Fc receptor (FcRn) at mucosal pH, compared to wildtype Ig Fc; and b) RBD is a receptor binding domain from or derived from SARS-CoV-2 spike protein, wherein the receptor binding domain comprises the amino acid sequence of SEQ ID NO. 13, or a fragment thereof, or an amino acid sequence having at least 80%, 85%, 90%, or 95% sequence identity to SEQ ID NO. 13. The invention further relates to a vaccine comprising said protein oligomer, preferably for use in active immunization and / or booster vaccination in a subject.

The invention discloses a giant salamander immune regulation meat peptide and application thereof. The meat peptide comprises one or more than two polypeptides selected from SEQ ID NOs: 1-5. The polypeptide can enhance cellular immune response, such as enhancing macrophage proliferation activity, improving macrophage nitric oxide secretion level, enhancing macrophage phagocytic ability, enhancing macrophage antigen presentation ability, enhancing immune organ functions, regulating T cell subpopulation, improving cellular immune factor level and enhancing immune globulin level.

The invention discloses a group of pyemia specific biomarkers and application thereof, and belongs to the field of medical detection.The biomarkers are formed by combination of alpha 1-microglobulin / Bikunin precursor protein and one or more of antithrombin III protein, apolipoprotein A1 or apolipoprotein H, according to the invention, seven core proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are screened from TMT proteomics of serum of a clinical hemorrhagic patient, and four more important proteins, namely APOA1, APOH, AMBP, SERPINC1, F2, FGG and FGB, are obtained by further screening the seven proteins in a hemorrhagic cell model and the clinical hemorrhagic patient. The four proteins are verified again in serum of a hemorrhagic mouse animal experiment and an expanded-scale clinical hemorrhagic patient, and the potential of the four core proteins as serum biomarkers for early diagnosis of hemorrhagic disease is determined.

The invention discloses functional recombinant soybean protein isolate emulsion gel as well as a preparation method and application thereof, and belongs to the technical field of soybean protein processing. The preparation method comprises the following steps: recombining three main components, namely soybean lipophilic protein, glycinin and beta-conglycinin, in soybean protein isolate (SPI) according to a certain compounding ratio, and carrying out combined modification on the recombined SPI by virtue of modification means such as ultrasonic treatment, heat treatment, magnetic field and enzyme crosslinking; the recombined SPI emulsion is subjected to micronization treatment by adopting high-pressure microjet homogenization treatment, and then the emulsion is jointly induced to be gelatinized by utilizing acid and salt ions and transglutaminase, so that the preparation efficiency, the structural strength and the stability of the emulsion gel are improved; two polyphenols, namely epigallocatechin gallate and quercetin, are co-embedded in an interface and an oil phase of the emulsion gel, so that the bioaccessibility and antioxidant activity of the polyphenols are improved, and the emulsion gel is endowed with functionality. The prepared emulsion gel can be widely applied to processing of functional food.

The invention discloses an enzymolysis preparation method of high-immunocompetence bovine coloctrum peptide, active peptide and application thereof, and belongs to the field of biotechnology and functional foods.The enzymolysis preparation method is characterized by comprising the steps that bovine coloctrum is degreased, trehalose is added into obtained supernate, first stirring is conducted, and first mixed liquid is obtained; wherein the supernate comprises whey protein and Ig; adding medium protease into the first mixed solution for hydrolysis to obtain enzymatic hydrolysate; wherein the enzymatic hydrolysate comprises a mixture of bovine colostrum hydrolyzed peptides, the Ig activity retention rate is larger than or equal to 90% through the targeted protection and directional enzymolysis technology, the beta-lactoglobulin peptide with the synergistic immune enhancement effect is obtained, the Ig and small molecule peptides in the product have the synergistic effect, the body immune regulation capacity and the intestinal immune function are remarkably improved, the immunity of the human body is improved, and the immunity of the human body is improved. The method can be widely applied to the fields of infant formulas, postoperative nutrition, functional drinks and the like.

The invention relates to the technical field of molecular markers, in particular to a molecular marker for early identification of immune traits of elephant male semi-fine wool sheep and application of the molecular marker. According to the present invention, the deterministic correlation between the genotype of the 102308292 site on the second chromosome and the immune globulin (IgA, IgG and IgM) level of the male semi-fine wool sheep is found for the first time; by detecting the genotype of the site, the future humoral immunity of the lamb can be predicted in the lamb stage, so that early seed selection is realized. The invention provides a powerful SNP marker for non-diagnostic purpose for disease-resistant breeding of male semi-fine wool sheep.

The invention provides application of lactobacillus rhamnosus GOLDGUT-M520 or a composition of the lactobacillus rhamnosus GOLDGUT-M520 in preparation of a product for enhancing the immunity of an organism. The lactobacillus rhamnosus GOLDGUT-M520 has the function of enhancing the immunity in both a viable form and an inactivated form of the lactobacillus rhamnosus GOLDGUT-M520. The lactobacillus rhamnosus GOLDGUT-M520 has a good antibacterial capability on escherichia coli and staphylococcus aureus which are pathogenic to intestinal tracts, and is beneficial to enhancing a chemical barrier in an innate immune barrier; the strain can improve the phagocytic activity of macrophages and enhance the innate immune response; the strain can improve the T cell proportion, the B cell proportion and the immune globulin level in mesenteric lymph nodes of immunocompromised mice, and can enhance adaptive immune response. The lactobacillus rhamnosus GOLDGUT-M520 can comprehensively play a role in enhancing immunity, and meanwhile, the inherent immune barrier, the inherent immune response and the adaptive immune response are enhanced.

The present disclosure provides novel immunoglobulin proteins that bind to a human natriuretic peptide receptor 1 (NPR1) agonist, preferably an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure comprise at least one immunoglobulin variable domain that binds to an anti-NPR1 antibody. In certain embodiments, the proteins of the disclosure are useful in blocking and / or reversing the effect of an administered anti-NPR1 antibody. In certain embodiments, the antigen-binding proteins are useful for effective management of blood pressure and hemodynamics in humans.

The invention relates to an aptamer specifically combined with beta-lactoglobulin and application of the aptamer, and belongs to the technical field of biological detection. According to the aptamer and the preparation method thereof, a binding domain base, participating in recognition, of the aptamer is predicted through molecular docking firstly, then the binding domain base is subjected to directional mutation, the aptamer with the recognition performance improved is obtained, the affinity of the aptamer to beta-lactoglobulin is 10.6 nM, and the aptamer has no recognition capacity on alpha-lactalbumin, casein, bovine serum albumin, immune globulin G, lactose and the like and can be used for preparing the aptamer with the recognition performance improved. Therefore, the aptamer disclosed by the invention has good sensitivity and specificity on the beta-lactoglobulin. On the basis, a fluorescence polarization method is directly constructed by utilizing the characteristic that the beta-lactoglobulin is a biomacromolecule, when the beta-lactoglobulin exists, an aptamer marked by a fluorophore FAM recognizes the beta-lactoglobulin to form an aptamer beta-lactoglobulin compound, and the fluorescence polarization value is relatively large, so that the beta-lactoglobulin compound can be used for identifying the beta-lactoglobulin. Therefore, the specific detection of the low-concentration beta-lactoglobulin is realized.

The present disclosure relates generally to immunoglobulin-related compositions (e.g., antibodies or antigen binding fragments thereof) that can bind to delta-like protein 3 (DLL3). The antibodies of the present technology are useful in methods for detecting and treating a DLL3-associated cancer in a subject in need thereof.

Provided herein are multispecific antigen-binding polypeptide constructs comprising at least two different heterodimers, each comprising a heavy chain and a light chain. At least one heterodimer comprises a Fab region comprising a lambda light chain and at least one heterodimer comprises a Fab region comprising a kappa light chain. One or more of the immunoglobulin heavy and light chains that form the antigen-binding polypeptide construct comprise amino acid modifications that promote correct pairing between the heavy and light chains to form the desired multispecific antigen-binding polypeptide construct. The amino acid modifications may be in the CH1 and / or CL domains, in the VH and / or VL domains, or a combination thereof.

A method and kit are provided for detecting anti-drug antibodies (ADAs) against self-assembling trimeric biologics, such as XPro1595, a pegylated variant of soluble human Tumor Necrosis Factor, in biological samples, particularly human serum. The method employs an Affinity Capture Elution-Protein A / G (ACE-AG) assay that overcomes non-specific reagent interactions inherent in conventional bridging and standard ACE assays due to the biologic's dynamic monomer exchange. The assay utilizes a two-plate system: a streptavidin-coated plate with biotinylated trimeric biologic captures ADAs, which are eluted, neutralized, and transferred to a protein A / G-coated plate for specific immunoglobulin capture and detection with a sulfo-tagged trimeric biologic via electrochemiluminescence. The kit includes pre-coated plates, labeled biologics, elution and neutralization solutions, assay buffer, confirmatory reagent, and instructions. The assay offers a robust, specific, and sensitive solution for immunogenicity testing of trimeric biologics.

The invention discloses a fusion protein taking peptide-N-glycosidase as an active component as well as a preparation method and application of the fusion protein, and belongs to the technical field of biological medicines. The fusion protein comprises: (a) peptide-N-glycosidase or a catalytically active fragment thereof; (b) an immunoglobulin Fc domain, or a combination of a tumor or immune cell antigen binding domain and an immunoglobulin Fc domain; (c) a linker peptide; wherein the form of the tumor or immune cell antigen binding domain is Fab, scFv or VHH; the peptide-N-glycosidase or the catalytic activity fragment of the peptide-N-glycosidase is connected with the Fc structural domain of the immunoglobulin through the connecting peptide; the immunoglobulin Fc domain mediates the fusion protein to form a homodimer or a heterodimer. According to the invention, the synergistic function of targeted binding and local deglycosylation of the target molecule is realized, so that the immunosuppressive activity of the target molecule is interfered, and the anti-tumor immune response is enhanced.

The invention relates to the technical field of molecular markers, in particular to an SNP (Single Nucleotide Polymorphism) molecular marker related to immune traits of male semi-fine wool sheep and application of the SNP molecular marker. The invention provides an SNP (Single Nucleotide Polymorphism) molecular marker related to immune traits of elephant male semi-fine wool sheep. The SNP molecular marker is positioned at the 24648039th basic group on the fifth chromosome of a Lanblet sheep reference genome ARS-UIRambv3.0, GCF016772045.2, and the SNP molecular marker is positioned at the 24648039th basic group on the fifth chromosome of the Lanblet sheep reference genome ARS-UIRambv3.0; the mutant basic group is G or T. By detecting the basic group of the 24648039th nucleotide site on the fifth chromosome of the elephant male semi-fine wool sheep, the content of immune globulins IgA, IgG and IgM of an elephant male semi-fine wool sheep individual can be judged, and a new SNP molecular marker resource is provided for non-diagnostic elephant male semi-fine wool sheep immune character marker-assisted selection.

The present application provides a recombinant fusion protein comprising a human activin receptor 2A extracellular domain optionally fused to an immunoglobulin heavy chain constant region via a linker wherein the human ACVR2A extracellular domain comprises a mutation from Asn (N) to Ala (A) at a site corresponding to position 24 of the sequence as shown in SEQ ID NO: 1 to remove glycosylation sites.

The present technology provides polypeptides comprising a first immunoglobulin single variable domain (ISVD) binding to albumin, a second ISVD capable of binding to both the constant domain of a human T cell receptor (TCR) on a T cell and the constant domain of a non-human primate TCR on a T cell, wherein said first and second ISVD are linked by a protease cleavable linker, and a targeting moiety. The present technology further provides nucleic acids encoding said polypeptides as well as vectors, hosts and methods to produce these polypeptides. Moreover, the present technology relates to methods for treatment making use of the polypeptides according to the present technology.

Tree pollen allergy is seasonal allergy caused by various tree pollen spread in air. The allergy affects a substantial proportion of populations, is particularly significant in European and North America areas, and is characterized by symptoms such as sneezing, nasal obstruction, rhinorrhea, eye itching and lacrimation, and throat irritation. The symptoms typically occur in spring, at which birch, alder, hazel and oak release pollen into the air. Tree pollen allergy is a type 1 hypersensitivity reaction mediated by an immunoglobulin E (IgE) antibody. The present invention relates to antibodies and antigen binding fragments thereof that bind to one or more of tree pollen allergens Bet v 1, Aln g 1, Cor a 1 and Quue a 1, resulting in inhibition of IgE-mediated anaphylaxis.

The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody as well as a hybridoma cell strain and application thereof, and belongs to the technical field of immune globulin. The invention provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody and also provides a hybridoma cell strain OTI10F11, the hybridoma cell strain OTI10F11 is preserved in the China General Microbiological Culture Collection Center on April 26, 2025, and the preservation number of the hybridoma cell strain OTI10F11 is No.46356. The invention further provides an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody. The hybridoma cell strain OTI10F11 provided by the invention can stably secrete an anti-human H < + > / K < + > ATPase beta protein monoclonal antibody, and can be specifically combined with H < + > / K < + > ATPase beta protein, so that the specificity, accuracy and reliability of immunodetection are remarkably improved, and the hybridoma cell strain OTI10F11 can be suitable for marking H < + > / K < + > ATPase beta protein in tissue cells.